TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17217576
Drug: Sucrose supplements
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose supplements (4 x 250 ml per day, providing 1800 kJ per day)
Study: 17217576
Drug: Sweetener supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetener supplements (4 x 250 ml per day, providing 67 kJ per day)
Study: 17217576
Drug: Sucrose supplements
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose supplements
Study: 17217576
Drug: Sweetener supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetener supplements
Study: 9669472
Drug: Nimodipine 90
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 90 mg daily for 12 weeks
Study: 24168756
Drug: Fluticasone (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (alone or in combination with salmeterol)
Study: 19800262
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid injections
Study: 18241753
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (CPAD-IC)
Study: 8881869
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion (0.5, 1, 2, 5 pmol.kg‐1.min‐1)
Study: 8881869
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion (5 pmol.kg‐1.min‐1)
Study: 6781657
Drug: Inhaled verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled verapamil (estimated dose 3 mg)
Study: 6781657
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (estimated dose 12 mg)
Study: 25873132
Drug: Pasireotide (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (long-acting release, 60 mg injection)
Study: 23347140
Drug: Enoxaparin with
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin with vitamin K antagonist (VKA)
Study: 21414740
Drug: FOLFOX4 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 regimen (oxaliplatin 85 mg/m(2) as a 2‐h infusion on day 1, leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Study: 21414740
Drug: LV5Fu2 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5Fu2 regimen (leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Study: 19707146
Drug: Ultrasonographic measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonographic measurement of antral area 2 h after ingestion of 200 ml of nonclear liquids
Study: 17689023
Drug: Capecitabine monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks, followed by capecitabine (650-1,000 mg/m2 orally twice daily 5 days/week) combined with radiotherapy for 5 weeks.
Study: 15279529
Drug: 2 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sessions of motivational enhancement therapy (MET)
Study: 15279529
Drug: 9 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 sessions of multicomponent therapy (including MET, cognitive-behavioral therapy, and case management)
Study: 11568588
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (GSH) treatment, 600 mg in 4 mL saline per day, administered via nasal aerosol in five 2-minute sessions every 3 or 4 waking hours for 2 weeks.
Study: 11568588
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mL saline per day), administered via nasal aerosol in the same manner as GSH treatment.
Study: 9272770
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (L-CHO)
Study: 1279497
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg flutamide for three months
Study: 1279497
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg flutamide for three months
Study: 1279497
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (500 mg and 750 mg)
Study: 22696517
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (pharmacological)
Study: 20386884
Drug: Oxycodone 20
Normalized name: oxycodone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 20 mg + 0.0001 mg NTX
Study: 20386884
Drug: Oxycodone 20
Normalized name: oxycodone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 20 mg + 0.001 mg NTX
Study: 20386884
Drug: Oxycodone 40
Normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 40 mg + 0.0001 mg NTX
Study: 20386884
Drug: Oxycodone 40
Normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 40 mg + 0.001 mg NTX
Study: 18541560
Drug: Micronutrient-fortified seasoning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified seasoning powder (5 mg Fe, 5 mg Zn, 50 mug I, 270 mug vitamin A per serving) consumed with school lunch 5 days/week
Study: 7483181
Drug: Medical strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical strategies with low to moderate doses of medication titrated over 12 weeks
Study: 27229348
Drug: Agomelatine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 50 mg/day
Study: 27229348
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg/day
Study: 20499349
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of zoledronate
Study: 11011338
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (1 to 4 mg/d)
Study: 11011338
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin treatment
Study: 8803378
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (SRM) administered at a 12‐hr interval
Study: 8803378
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (SRM)
Study: 1454315
Drug: Timolol 0.25%
Normalized name: Timolol 0.25% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.25% or 0.5% twice daily
Study: 1454315
Drug: Pilocarpine 2%
Normalized name: PILOCARPINE 2% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 2% or 4% four times daily
Study: 6609521
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (Abboticin) in standard dosage for the last 10 days before surgery
Study: 28506134
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg BIW
Study: 28506134
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg QW
Study: 24429167
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MTX and etanercept
Study: 20651609
Drug: Heterozygous (GA)
Normalized name: Heterologous human adult liver derived progenitor cells
DrugBank: Heterologous human adult liver derived progenitor cells (DB17695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterozygous (GA) for the FPGS IVS1 (28) G>A polymorphism
Study: 17365851
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil (9.9 g dose)
Study: 16305652
Drug: rHuEpo administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rHuEpo administration for 6 months
Study: 11889776
Drug: Droperidol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5.0 mg
Study: 11889776
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of 0.25% bupivacaine 40 ml and buprenorphine 0.4 mg
Study: 7616870
Drug: Combined norethisterone
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined norethisterone acetate (NETA)/oestradiol (E2)‐TTS, delivering 0.25 mg NETA and 50 micrograms E2 per day, continuously for 12 calendar months
Study: 1967425
Drug: Soluble prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble prednisolone (20 mg twice daily on days 1-10 of the female partner's menstrual cycle, followed by 5 mg on days 11 and 12)
Study: 326101
Drug: Flunisolide aerosol
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide aerosol administered every 12 hours for eight weeks
Study: 28363933
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg and 0.5 mg)
Study: 22835606
Drug: Specific oral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific oral tolerance induction (SOTI) with powdered pasteurised egg, starting with 1mg and increasing weekly to 10g over an average duration of 10 weeks.
Study: 19925284
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg for six months (Group 1)
Study: 10474065
Drug: Org 4428
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 4428 (25 mg)
Study: 10474065
Drug: Org 4428
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 4428 (100 mg)
Study: 8683634
Drug: Combined adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined adjuvant chemotherapy and radiation therapy
Study: 8683634
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy alone
Study: 6822108
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 5 to 30 mg
Study: 29669001
Drug: Pneumococcal Conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal Conjugate Vaccine 10
Study: 29669001
Drug: Pneumococcal Conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal Conjugate Vaccine 13
Study: 27033905
Drug: Dexketoprofen 1
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 1 mg/kg IV (group DK)
Study: 27033905
Drug: Methadone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 0.2 mg/kg IV (group M)
Study: 14720266
Drug: TBC1269 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBC1269 (30 mg/kg)
Study: 11223496
Drug: ProBAN sublingual
Normalized name: Probanthine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProBAN sublingual tablets and nicotine gum
Study: 11223496
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and nicotine gum
Study: 1088099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline on admission and 100 mg on the second day
Study: 1088099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline on admission only
Study: 1088099
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of doxycycline on admission only
Study: 1088099
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of tetracycline every 6 h for 48 h
Study: 31925529
Drug: 23-month ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23-month ticagrelor monotherapy after 1-month ticagrelor and aspirin dual anti-platelet therapy (DAPT)
Study: 31925529
Drug: 12-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month DAPT followed by 12-month aspirin
Study: 28685712
Drug: Shensong Yangxin
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shensong Yangxin capsules (SSYX)
Study: 23307069
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg of CBD administered post-extinction
Study: 23307069
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg of CBD administered before extinction
Study: 19165663
Drug: 750 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 IU of hCG every three days during endometrial preparation with estradiol
Study: 16500921
Drug: Propranolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol infusion with mixed liquid meal (700 kcal)
Study: 14985214
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine (0.6 g.kg(‐1).d(‐1))
Study: 9420391
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg plain water orally 3 hours before surgery
Study: 9420391
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg plain water and 2 mg/kg of ranitidine orally 3 hours before surgery
Study: 30911906
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (50 mg) with high-fat meal consumption 30 min before administration
Study: 30911906
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (50 mg) sprinkled on applesauce
Study: 30911906
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (50 mg) fasting (reference treatment)
Study: 26925901
Drug: Blind corticosteroid
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind corticosteroid injection
Study: 22646219
Drug: Desvenlafaxine 150
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 150 mg/day
Study: 20827547
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg orally once weekly
Study: 9655733
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone (60 mg/d for 1 month, tapered to 40 mg/d for the second month, then 40 mg every other day during the third month)
Study: 9655733
Drug: Colchicine (0.6-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.6-1.2 mg/d, as tolerated)
Study: 2665493
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU oxytocin administered into the umbilical veins
Study: 870096
Drug: Marijuana cigarette
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana cigarette (18 mg of delta‐9‐THC)
Study: 870096
Drug: Placebo marijuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo marijuana cigarette (0.05 mg of delta‐9‐THC)
Study: 11375826
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of propofol and small-dose ketamine (propofol 33 +/- 13 microg x kg(‐1) x min(‐1) and ketamine 3.7 +/- 1.5 microg x kg(‐1) x min(‐1))
Study: 11375826
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of propofol and small-dose ketamine
Study: 31500605
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) + Androgen deprivation therapy (ADT)
Study: 29490289
Drug: DHEA co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA co-administration
Study: 17585117
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human [rDNA Origin] insulin
Study: 15172365
Drug: CMC‐001 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMC‐001 (0.8 g MnCl2)
Study: 15172365
Drug: CMC‐001 (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMC‐001 (1.6 g MnCl2)
Study: 9655270
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin intravenously every 8 hours
Study: 7815722
Drug: Drip Infusion
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip Infusion Cholecystography (DIC)
Study: 30734629
Drug: Fentanyl-soaked Merocel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl-soaked Merocel® packing (50 mcg)
Study: 22813235
Drug: BRV 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 150 mg/day
Study: 21950702
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of Avastin
Study: 21950702
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg Macugen
Study: 21950702
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (1 mg Avastin followed by 0.3 mg Macugen)
Study: 10600092
Drug: rhIGF‐1 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐1 0.01 mg/kg/hour and daily subcutaneous doses of rhGH 0.05 mg/kg/day
Study: 7864425
Drug: esmolol, 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol, 1.3 mg/kg
Study: 7864425
Drug: esmolol, 4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol, 4.4 mg/kg
Study: 7864425
Drug: labetalol, 0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol, 0.13 mg/kg
Study: 7864425
Drug: labetalol, 0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol, 0.44 mg/kg
Study: 2167806
Drug: Intralipid (10%)
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (10%) and heparin (Lipid)
Study: 6796270
Drug: Chlordesmethyldiazepam 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam 2 mg (CDDZ2)
Study: 6796270
Drug: Chlordesmethyldiazepam 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam 1 mg (CDDZ1)
Study: 24692816
Drug: Candesartan (8-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8-12 mg/d)
Study: 16793604
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg/kg bolus followed by 0.5 mg.kg(‐1).h(‐1) infusion)
Study: 12658084
Drug: Topical azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical azelastine 0.02%
Study: 12658084
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (0.2 mg/10 mL)
Study: 9143790
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after withdrawal from therapy
Study: 29265884
Drug: Xbox Kinect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xbox Kinect exergames played twice weekly for 8 weeks
Study: 18190664
Drug: Opioid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid treatment exposure longer than 7 days
Study: 18190664
Drug: Older participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older participants randomized to buprenorphine treatment
Study: 15864409
Drug: Electrolytic iron
Normalized name: electrolytic iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrolytic iron with 50 mg ascorbic acid (AA)
Study: 9337181
Drug: gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil 1200 mg/d
Study: 2566048
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin 10 mg/kg per day
Study: 2566048
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg orally per day
Study: 794686
Drug: Tibezonium iodide
Normalized name: tibezonium iodide
DrugBank: Tibezonium iodide (DB13702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibezonium iodide tablets
Study: 28651370
Drug: Metformin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin administered 850 mg twice a day
Study: 20079208
Drug: HD‐DXM +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐DXM + RM group (40 mg/d of dexamethasone in a 4‐day pulse every 14 days for 3 cycles + 0.035 mg x kg(‐1) x d(‐1) for maintenance)
Study: 20079208
Drug: HD‐DXM +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐DXM + SM group (40 mg/d of dexamethasone in a 4‐day pulse every 14 days for 3 cycles + 0.035 mg x kg(‐1) x d(‐1) only when platelet count < 20 x 10(9)/L)
Study: 20079208
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine dosage of prednisone)
Study: 15080375
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of alcohol for 7 days
Study: 55895
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (400 mg daily) for 1 week before and 1 week after 5 mCi therapy dose of 131I
Study: 55895
Drug: 5 mCi
Normalized name: iobenguane I-131 15 MCI/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mCi of 131I without lithium therapy
Study: 25664999
Drug: Multi-nutrient supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient supplement (550 mg DHA, 550 mg EPA, 10 µg vitamin D3 and 8 g whey protein)